AlphaGrep UK
UTHR icon

AlphaGrep UK’s United Therapeutics UTHR Stock Holding History

AlphaGrep UK’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$532K Sell
981
-562
-36% -$291K 0.16% 213
2026
Q2 		$836K Buy
1,543
+1,074
+229% +$605K 0.25% 76
2026
Q1 		$278K Buy
+469
New +$234K 0.08% 551

Other funds holding UTHR

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

AlphaGrep UK's UTHR Position: Q3 2026 in Review

AlphaGrep UK reduced its United Therapeutics (UTHR) stake by 36% in Q3 2026, selling an estimated $291K and leaving 981 shares worth $532K. The position accounts for 0.16% of the portfolio, ranked #213.

AlphaGrep UK first reported a position in UTHR in Q1 2026 and has held it in 3 quarters since. The position peaked at $836K in Q2 2026. 673 funds tracked by Wall St. Rank hold UTHR as of Q3 2026.

  • AlphaGrep UK held 981 shares of United Therapeutics worth $532K as of Q3 2026.
  • AlphaGrep UK sold 562 United Therapeutics shares in Q3 2026, an estimated $291K.
  • United Therapeutics made up 0.16% of AlphaGrep UK's portfolio in Q3 2026, its #213 holding.
  • AlphaGrep UK first reported a position in United Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • AlphaGrep UK's United Therapeutics position peaked at $836K in Q2 2026.
  • 673 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2026.

Based on AlphaGrep UK's 13F filing for Q3 2026, filed 12 Nov 2026.